Le Lézard
Classified in: Health
Subject: PER

HAVAS HEALTH APPOINTS PFIZER'S ANNA MARIA MARRA AS EUROPE CEO


After over 22 years at Pfizer, Anna Maria Marra will helm Havas Health's European branch to expand global operations, capabilities and growth.

NEW YORK, Nov. 12, 2024 /CNW/ - Havas Health has appointed Anna Maria Marra?as CEO of Europe to lead and oversee all aspects of the region's business operations. 

Marra's prowess for overseeing cross-functional teams and driving global blockbuster pharmaceutical brand launches has solidified her reputation as a leader who can effectively navigate complex markets to drive significant growth. In her new role as Havas Health's CEO of Europe,?Marra?will continue to leverage her industry-renowned ability to penetrate different regional markets to deliver client results. 

Her career spans more than 26 years across four continents, during which she has held key leadership roles in marketing, sales, and operations at Organon, MSD, and, most recently, Pfizer. In her previous role, she led the global marketing for Emblaveo®, a novel antibiotic for hospital and specialty care, helping to bring this lifesaving drug to market to support the fight against antimicrobial resistance. 

"My experience has equipped me with deep insight on how to best apply digital trends to marketing innovation on a global and regional scale," shared Marra. "I've long admired the work coming out of Havas Health and am thrilled to be joining an organization at the forefront of healthcare marketing transformation." 

All European agency CEOs will now report to Marra, and she will report to?Donna Murphy, Global Chief Executive Officer of Havas Health and Havas Creative Networks. 

"Having Anna Maria onboard to lead Europe will undoubtedly make a meaningful impact on our clients and their businesses," said Murphy. "Her breadth of global brand commercialization and pharmaceutical product expertise will give Havas Health a strategic new edge, and I look forward to seeing all she accomplishes as we gain momentum into 2025." 

ABOUT HAVAS HEALTH NETWORK 
Havas Health Network unites Havas Life, Havas Lynx,?and Jacques, all wholly owned health and communications networks, with the consumer health businesses and practices of Havas Creative Group. The network's approach is centered around making a meaningful difference and has the talent, tenacity, and technology that health companies, brands, and people need to thrive in today's world. For more information, visit?www.HavasHealth.com

SOURCE Havas Health Network


These press releases may also interest you

at 15:30
Anthony "Tony" Van Heugten, the Chief Technology...

at 15:05
Merck , known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, Merck's investigational antibody drug conjugate (ADC) that targets...

at 15:00
AbbVie announced groundbreaking results today from its latest Emotional Impact Report (EIR), a patient survey that provides an understanding of the mental...

at 15:00
SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., presented data at the American Epilepsy Society (AES) Annual Meeting, showcasing its antiseizure...

at 12:55
Vertex Pharmaceuticals Incorporated today announced longer-term data for CASGEVYtm (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the...

at 12:35
Kite, a Gilead Company , today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were...



News published on and distributed by: